Published in Nat Rev Drug Discov on January 01, 2005
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov (2012) 5.55
How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol (2010) 4.65
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. BMC Bioinformatics (2010) 2.94
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64
Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol (2009) 2.52
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 2.33
Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell (2009) 2.27
Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol (2008) 2.01
Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinformatics (2010) 2.00
Combination chemical genetics. Nat Chem Biol (2008) 1.98
Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol (2011) 1.98
Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep (2009) 1.97
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol (2011) 1.51
Genome-environment interactions that modulate aging: powerful targets for drug discovery. Pharmacol Rev (2011) 1.42
A global view of drug-therapy interactions. BMC Pharmacol (2008) 1.34
Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies. Mol Cell Proteomics (2013) 1.34
Accurate, precise modeling of cell proliferation kinetics from time-lapse imaging and automated image analysis of agar yeast culture arrays. BMC Syst Biol (2007) 1.33
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A (2008) 1.27
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One (2007) 1.25
Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol (2011) 1.25
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
High-order combination effects and biological robustness. Mol Syst Biol (2008) 1.24
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24
Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol (2010) 1.23
Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc Natl Acad Sci U S A (2012) 1.17
Phytotherapy in diabetes: Review on potential mechanistic perspectives. World J Diabetes (2014) 1.14
A call for using natural compounds in the development of new antimalarial treatments - an introduction. Malar J (2011) 1.14
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform (2012) 1.09
Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect (2015) 1.08
A yeast phenomic model for the gene interaction network modulating CFTR-ΔF508 protein biogenesis. Genome Med (2012) 1.06
Emergence and natural selection of drug-resistant prions. Mol Biosyst (2010) 1.05
Biological screening of natural products and drug innovation in China. Philos Trans R Soc Lond B Biol Sci (2007) 1.04
Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol (2009) 1.04
Networks from drug-drug surfaces. Mol Syst Biol (2007) 1.01
Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther (2009) 1.00
Tinnitus: network pathophysiology-network pharmacology. Front Syst Neurosci (2012) 0.99
Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm (2014) 0.98
Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol Syst Biol (2015) 0.98
Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol (2007) 0.98
Molecular networks in drug discovery. Crit Rev Biomed Eng (2010) 0.98
Deciphering diseases and biological targets for environmental chemicals using toxicogenomics networks. PLoS Comput Biol (2010) 0.98
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine (2012) 0.96
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 0.94
Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer. Mol Pharm (2014) 0.94
Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol (2012) 0.94
Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis (2007) 0.94
Synergistic and antagonistic drug combinations depend on network topology. PLoS One (2014) 0.92
Discovery of antibiotic adjuvants. Nat Biotechnol (2013) 0.91
Rationally designed multitarget agents against inflammation and pain. Curr Med Chem (2013) 0.91
Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform (2015) 0.90
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int (2007) 0.89
High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. ACS Med Chem Lett (2015) 0.89
Network pharmacology: a new approach for chinese herbal medicine research. Evid Based Complement Alternat Med (2013) 0.89
Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc Natl Acad Sci U S A (2015) 0.89
Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol (2014) 0.88
Evaluation of antibiotic & antibiotic modifying activity of pilocarpine & rutin. Indian J Med Res (2012) 0.88
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics (2009) 0.87
Synergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice model. PLoS One (2012) 0.87
A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines. Sci Rep (2015) 0.86
Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface (2016) 0.85
Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? BMC Neurol (2011) 0.85
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. PLoS One (2014) 0.85
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol (2013) 0.84
Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS One (2014) 0.84
Systematic discovery of drug interaction mechanisms. Mol Syst Biol (2015) 0.84
Exploiting genomic knowledge in optimising molecular breeding programmes: algorithms from evolutionary computing. PLoS One (2012) 0.84
Evaluation of the antifungal activity and modulation between Cajanus cajan (L.) Millsp. leaves and roots ethanolic extracts and conventional antifungals. Pharmacogn Mag (2012) 0.84
Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo. Adv Healthc Mater (2014) 0.84
Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2. J Carcinog (2005) 0.83
Platelet aggregation pathway network-based approach for evaluating compounds efficacy. Evid Based Complement Alternat Med (2013) 0.83
Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem (2013) 0.83
Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci U S A (2011) 0.83
Shape and evolution of the fundamental niche in marine Vibrio. ISME J (2012) 0.83
Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol (2016) 0.82
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther (2015) 0.82
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One (2013) 0.82
Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis. Nat Commun (2016) 0.82
Polyactives: controlled and sustained bioactive release via hydrolytic degradation. Biomater Sci (2015) 0.81
A network perspective on unraveling the role of TRP channels in biology and disease. Pflugers Arch (2013) 0.81
Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Syst Biol (2011) 0.81
Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Syst Biol (2012) 0.81
Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology. Sci Rep (2016) 0.81
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. Clin Cancer Res (2015) 0.81
Systems biology and cancer prevention: all options on the table. Gene Regul Syst Bio (2008) 0.80
Molecular insights into the anti-cancer properties of traditional Tibetan medicine Yukyung Karne. BMC Complement Altern Med (2014) 0.80
alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate. Br J Cancer (2010) 0.80
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 6.31
Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci U S A (2003) 4.68
Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 3.86
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature (2007) 3.21
PathBLAST: a tool for alignment of protein interaction networks. Nucleic Acids Res (2004) 3.20
Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol (2010) 3.01
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol (2008) 2.04
Combination chemical genetics. Nat Chem Biol (2008) 1.98
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat Chem Biol (2010) 1.62
Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc (2014) 1.49
Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc Natl Acad Sci U S A (2004) 1.48
Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol (2004) 1.45
Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci U S A (2011) 1.45
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One (2007) 1.25
Biological mechanism profiling using an annotated compound library. Chem Biol (2003) 1.23
Protein folding drives disulfide formation. Cell (2012) 1.18
A flexible data analysis tool for chemical genetic screens. Chem Biol (2004) 1.15
Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol (2008) 1.15
Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet (2006) 1.14
Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett (2011) 1.10
Detecting spatial patterns in biological array experiments. J Biomol Screen (2003) 1.06
The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res (2007) 1.06
Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci U S A (2007) 1.02
Functional model of metabolite gating by human voltage-dependent anion channel 2. Biochemistry (2011) 1.00
Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther (2009) 1.00
Selective inhibitors of death in mutant huntingtin cells. Nat Chem Biol (2006) 0.99
Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA (2006) 0.99
Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency. ACS Med Chem Lett (2011) 0.98
Advances in chemical genetics. Annu Rev Genomics Hum Genet (2005) 0.97
Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol Syst Biol (2010) 0.97
Using small molecules to overcome drug resistance induced by a viral oncogene. Cancer Cell (2006) 0.96
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 0.94
Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol (2008) 0.92
Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death. Bioorg Med Chem Lett (2012) 0.92
Identifying druggable disease-modifying gene products. Curr Opin Chem Biol (2009) 0.91
Eliminating membrane depolarization caused by the Alzheimer peptide Abeta(1-42, aggr.). Biochem Biophys Res Commun (2002) 0.89
Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol (2015) 0.89
Global analysis of large-scale chemical and biological experiments. Curr Opin Drug Discov Devel (2002) 0.85
Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol (2012) 0.84
Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway. J Biol Chem (2010) 0.84
High throughput screening for neurodegeneration and complex disease phenotypes. Comb Chem High Throughput Screen (2008) 0.84
Restoring functions of tumor suppressors with small molecules. Cancer Cell (2003) 0.83
Chemical genetic approaches to probing cell death. Curr Opin Chem Biol (2006) 0.83
Therapeutic selectivity and the multi-node drug target. Discov Med (2009) 0.81
Chemical genetics and orphan genetic diseases. Chem Biol (2005) 0.81
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther (2012) 0.80
A novel role for jun N-terminal kinase signaling in olfactory sensory neuronal death. Mol Cell Neurosci (2008) 0.80
Identification of a small molecule that induces ATG5-and-cathepsin-l-dependent cell death and modulates polyglutamine toxicity. Exp Cell Res (2013) 0.78
Chemical biology: renewing embryonic stem cells. Nature (2006) 0.77
A mammalian cell-based assay for screening inhibitors of RNA cleavage. Methods Mol Biol (2009) 0.77
Drug discovery: engineering drug combinations. Nat Chem Biol (2010) 0.77
Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins. ACS Chem Biol (2013) 0.76
The biological magic behind the bullets. Nat Biotechnol (2004) 0.75
Enzyme annotation with chemical tools. Chem Biol (2006) 0.75
Discovery of Anticancer Agents of Diverse Natural Origin. J Nat Prod (2022) 0.75